ChronicleBio

: Dr. John Mumm, Chief Scientific Officer

Dr. Mumm has spent his career in immuno-oncology helping precision medicine transform cancer care. For him, it wasn't just about discovering new therapies, but understanding that what looked like one disease was actually many. With the right biomarker, the right patient, and the right therapy, outcomes changed.

Now he's bringing that same thinking to complex chronic conditions.

“The system has effectively given up on millions of patients because their syndromes have long been thought to be too complex to take on, but we know they are actually tractable molecular problems we can solve with the right therapeutic targets. That gap between what's possible and what has been done is what motivates me," Mumm said.

Mumm is a three-decade immunology innovator who has founded multiple companies and authored more than 30 peer-reviewed publications. He brings transformational drug-development expertise to Chronicle.

“This team treats every patient sample as a falsifiable hypothesis rather than a data point,” Mumm said. “That intellectual honesty is rare, and it’s the only mindset that actually moves potential treatments for chronic disease forward.”

That conviction is what brought him to ChronicleBio as Chief Scientific Officer. For the patients who have spent years searching for answers, his message is clear: Your disease is not unsolvable. It just hasn't been solved yet.

That's .

For the first time, members of the ChronicleBio science team came together in person as we prepare to open our lab and headquarters. What started as a mission shared across screens, states, and lived experiences is becoming something very real.

These are the incredible researchers who are analyzing your data, biospecimens, and wearable device insights. They’re building our AI model to find better diagnostics and treatments for complex chronic conditions faster.

Moments like this remind us how far this mission has already come in just a year. If you participate in our studies you’ve likely seen us write, “with gratitude from the lab.” Now you know a few of the faces behind it.

We can’t wait to share more from our new lab soon!

Our scientists have come from various backgrounds. Their journeys to ChronicleBio are unique and meaningful. We are grateful the path to discovery led them to our team! Read about Cortney Gensemer, PhD’s experience below.

Am I still working on EDS? Yes. More than ever. A lot of you have asked. So, I wrote about leaving academia and what “being a scientist” can look like, what a PhD really gives you, and how I found my way to ChronicleBio.

Becoming a mom forced me to reevaluate the way I was doing research. That pivot allowed me to uncover a system I didn’t even know existed outside of the walls of academia. Spending 60+ hours a week in a lab took a toll on my health, but the intensity that academia rewards is the same intensity that undoes the careful work I’ve put in to keep myself functional. I spent a long time thinking that staying in academia was the price of doing this work seriously. It wasn’t.

What I’ve discovered since leaving is that some of the most brilliant, patient-relevant work in the chronic illness space is happening outside of academic institutions. In my latest blog, I share how I made the decision to leave and what life as a scientist looks like now.

https://open.substack.com/pub/cortneygensemer/p/leaving-academia-not-leaving-the?r=1yhgid&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true

For patients with EDS, finding a clinician who truly understands their condition can take years. Dr. Dacre Knight has dedicated his career to changing that.

We're proud to introduce Dr. Knight as a Scientific Advisory Board Member and Medical Director of our research studies. As the founder of the EDS Clinic at Mayo Clinic, and now the Medical Director of the Center for EDS and Hypermobility Disorders at UVA, he brings unparalleled clinical expertise to our platform and a deep understanding of what this patient population needs from science.

Dr. Knight is also a researcher at the forefront of applying AI to improve diagnostic medicine. His vision aligns directly with what ChronicleBio is building: a data platform that moves beyond symptom management and toward the underlying biology of complex chronic disease.

We exist to change outcomes like this.

ChronicleBio Co-founder Fidji Simo recently announced she is taking medical leave from OpenAI due to Postural Orthostatic Tachycardia Syndrome (POTS).

It is a jarring reminder of why our entire team is working fast and hard. Simo is one of millions of people facing life-altering symptoms and difficult decisions because of them.

Conditions like POTS, ME/CFS, and Long COVID, which frequently overlap, remain poorly understood, leaving patients without FDA-approved treatments. At ChronicleBio, we are building a multimodal data platform designed to unlock answers by combining biospecimens, wearable data, and clinical records to generate AI-driven insights into disease biology.

The research is complex, but our goal remains simple. We aim to move from fragmented understanding to actionable insight to targeted therapies so patients like Fidji can get better, sooner.

In just our first year, hundreds of participants have enrolled in the Chronicle I Study through our clinic partners around the world. Our scientists are already generating early signals across complex chronic conditions and have identified multiple potential drug targets.

So, to our courageous co-founder, and all patients who have lost pieces of their identities to chronic illness:

We know why we are here.
We know what is at stake.
We are determined.

With love from the lab,
The ChronicleBio Team